Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice.

HSV-1 mutants in the RL-1 gene encoding the ICP34.5 protein have been demonstrated to have diminished neurovirulence in brain yet replicate as efficiently as parental virus in transformed tissue culture cells. Thus they have been proposed as candidates viruses for human brain tumor therapies. Evaluation of their replicative properties and pathogenesis within the nervous system has been limited. As most patients undergoing therapies for brain tumors are likely to be immunocompromised, it will be important to understand the pathogenesis of these viruses in immunocompromised hosts. To this end, the lateral ventricle of nude mice was injected with high (2.5 x 10(7) PFU), medium (10(5) PFU), or low dose (10(3) PFU) HSV-1 variant-1716, which has a deletion in the RL-1 gene. Ten of 10 mice died within 2-3 days following the high titer infection. Six of 19 animals with medium titer infection died within 9 days, and viral antigens were seen in ependymal cells as well as neurons within the brainstem and thalamus. Although only two of 19 animals became moribund 18 days after medium titer viral infection, many neocortical and hippocampal neurons were positive for HSV-1 antigens. However, plaque-purified viral isolates recovered from brain homogenates of these animals demonstrated no increase in pathogenicity. Nine of 20 animals died following low dose infection; six of these animals, from which tissue was analyzed, all had many HSV antigen-positive neurons in the neocortex and hippocampus. These data imply that if this type of virus is used for human brain tumor therapy immunosuppressed patients may suffer from significant viral pathogenesis outside the tumor.

[1]  I. Mohr,et al.  Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene , 1997, Journal of virology.

[2]  B. Roizman,et al.  The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1 , 1997, Journal of virology.

[3]  S. Berger,et al.  Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures , 1997, Journal of virology.

[4]  J. Trojanowski,et al.  Therapy of a Murine Model of Pediatric Brain Tumors using a Herpes Simplex Virus Type‐1 ICP34.5 Mutant and Demonstration of Viral Replication within the CNS , 1996, Journal of neuropathology and experimental neurology.

[5]  J. Trojanowski,et al.  Selective Vulnerability of Mouse CNS Neurons to Latent Infection with a Neuroattenuated Herpes Simplex Virus-1 , 1996, The Journal of Neuroscience.

[6]  I. Mohr,et al.  A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. , 1996, The EMBO journal.

[7]  A. Nesburn,et al.  The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation , 1996, Journal of virology.

[8]  B. Roizman,et al.  Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Trojanowski,et al.  Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[10]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[11]  L. Soroceanu,et al.  Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Brown,et al.  Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. , 1994, The Journal of general virology.

[13]  B. Roizman,et al.  Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Deshmane,et al.  A thymidine kinase-negative HSV-1 strain establishes a persistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement. , 1994, Virology.

[15]  R. Martuza,et al.  Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. , 1993, Neurosurgery.

[16]  S. Deshmane,et al.  Herpes simplex virus type 1 mutant strain in1814 establishes a unique, slowly progressing infection in SCID mice , 1992, Journal of virology.

[17]  S. Brown,et al.  Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. , 1991, The Journal of general virology.

[18]  B. Roizman,et al.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. , 1990, Science.

[19]  L. J. Perry,et al.  The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. , 1988, The Journal of general virology.

[20]  D. Springall,et al.  The immunocytochemical detection of Herpes simplex virus in cervical smears—a valuable technique for routine use , 1984, The Journal of pathology.

[21]  R. L. Thompson,et al.  Biological characterization of a herpes simplex virus intertypic recombinant which is completely and specifically non-neurovirulent. , 1983, Virology.

[22]  P. Pignatti,et al.  Herpes simplex virus DNA isolation from infected cells with a novel procedure. , 1979, Virology.